Samsung Pharm to Pursue ISO Certifications for Anti-Corruption and Compliance
Samsung Pharm will introduce international certifications related to anti-corruption and compliance management.
On March 19, Samsung Pharm announced that it is seeking to obtain the International Organization for Standardization (ISO) certifications for the “Anti-Bribery Management System (ISO 37001)” and the “Compliance Management System (ISO 37301).” The company explained that this initiative aims to enhance corporate transparency and establish a compliance management system that meets global standards.
ISO 37001 is an international standard that helps organizations establish and effectively operate anti-bribery management systems. ISO 37301 is a management system for systematically overseeing obligations that companies must comply with, including laws, regulations, and codes of ethics.
Samsung Pharm plans to integrate both certification systems to not only prevent corruption, but also to instill a culture of compliance across all business areas, including sales, production, and research and development. To this end, the company will select internal auditors, proactively identify potential risks during the certification implementation and operation process, and provide both employee education and internal audits in parallel.
A company representative stated, “By pursuing ISO certification, we will strengthen stakeholder trust and lay the foundation for sustainable growth based on transparent and fair business practices. We will further enhance our company-wide compliance management system and foster a responsible corporate culture that meets global standards.”
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Trump’s Approval Rating Drops to 37%, Lowest Since Return to Office
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Meanwhile, Samsung Pharm, a domestic pharmaceutical company established in 1929, has been working to strengthen its competitiveness in the pharmaceutical sector while transitioning into a new drug development company. Most recently, through a technology transfer with GemVax & KAEL, it secured clinical development and commercialization rights for the progressive supranuclear palsy (PSP) treatment GV1001 in four key Asian countries, including Korea, and has applied for conditional item approval from the Ministry of Food and Drug Safety.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
